Shanghai-based Immunocan, a biotech firm specializing in next-generation antibody discovery, has successfully closed a RMB 250 million Series A financing round. The investment was led by Vivo Capital, with significant participation from Gold Mine Multi Family Office and continued backing from existing investors Kingray Capital and TigerYeah Capital. These funds are earmarked to enhance the company's innovative gene-edited animal platforms and expand its AI-driven drug discovery capabilities.
Pioneering Antibody Discovery Platforms
At the core of Immunocan's innovation is its proprietary MASIRT® technology, which enables large-scale, in-situ DNA replacement across different species. This gene-editing breakthrough significantly accelerates the creation of advanced animal models for therapeutic antibody research. The technology's ability to handle massive DNA fragments in a single operation streamlines the development process for fully human antibody platforms.
The company has built a comprehensive portfolio of multi-species platforms, including fully human mouse and rabbit models. A key differentiator is its globally unique ImmuAlpaca® platform, which produces alpaca-derived antibodies in mice, filling a critical gap in the market. This diverse offering provides researchers with powerful tools to generate high-quality antibodies for a wide range of therapeutic targets.
Integrating Artificial Intelligence
Immunocan is further enhancing its discovery engine by integrating artificial intelligence through its MabAI® platform. This system leverages the vast datasets, exceeding 100 million sequences annually, generated from its diverse animal models. The platform applies AI to model antibody generation and characterization, significantly improving screening efficiency and predicting drug developability.
This dual-engine approach, combining fully human model animals with AI empowerment, creates a powerful synergy for drug development. By integrating high-quality biological data with advanced computational models, Immunocan aims to drastically shorten research and development timelines. This innovative system is designed to increase the success rate of identifying promising new antibody drug candidates.
Strategic Growth and Market Validation
The new capital will be strategically deployed to accelerate several key initiatives for the company. Primary objectives include advancing the research of its gene-edited animal platforms and driving the commercialization of its fully human antibody rabbit platform. The funding will also support the establishment of the AI screening platform and the expansion of its scientific team.
The industrial value of Immunocan's technology has already been validated through robust collaborations with leading pharmaceutical companies. The firm has established partnerships with numerous domestic and international drugmakers, including several of the world's top 10 multinational corporations. These partnerships underscore the market's confidence in the platform's ability to deliver innovative therapeutic solutions.
Investor Confidence and Future Outlook
The successful financing round highlights strong investor confidence in Immunocan's differentiated technological approach and future potential. The leadership from Vivo Capital, coupled with strong follow-on investments from existing backers, signals a firm belief in the company's vision. This support provides a solid foundation for Immunocan to pursue its ambitious growth and innovation goals.
Dr. Zhang Jiwei, founder of Immunocan, described the financing as a pivotal milestone that will fuel the company's strategic transformation. He emphasized the commitment to leveraging their core technologies to support biomedical innovation and expand their global industrial cooperation ecosystem. The ultimate goal is to build an internationally leading antibody discovery platform to benefit patients worldwide.
This RMB 250 million investment positions Immunocan to significantly scale its operations and solidify its leadership in the antibody discovery field. By advancing its unique gene-edited animal models and integrating them with a sophisticated AI platform, the company is well-equipped to tackle complex drug development challenges. The funding will accelerate its mission to provide more efficient research solutions and deliver breakthrough therapies to the global market.